Use of Recombinant Parainfluenza Viruses (PIVS) as Vectors To Protect Against Infection and Disease Caused By PIV and Other Human Pathogens Read more about Use of Recombinant Parainfluenza Viruses (PIVS) as Vectors To Protect Against Infection and Disease Caused By PIV and Other Human Pathogens China00805939.XFiled on 2000-12-08
Use of Recombinant Parainfluenza Viruses (PIVs) as Vectors to Protect against Infection and Disease Caused by PIV and Other Human Pathogens Read more about Use of Recombinant Parainfluenza Viruses (PIVs) as Vectors to Protect against Infection and Disease Caused by PIV and Other Human Pathogens Canada2362685Filed on 2000-12-08
Use of Recombinant Parainfluenza Viruses (PIV's) as Vectors To Protect Against Infection and Disease Caused By PIV and Other Human Pathogens Read more about Use of Recombinant Parainfluenza Viruses (PIV's) as Vectors To Protect Against Infection and Disease Caused By PIV and Other Human Pathogens BrazilPI0105530-5Filed on 2001-11-28
Use of Recombinant Parainfluenza Viruses (PIVs) as Vectors To Protect Against Infection and Disease Caused By PIV and Other Human Pathogens Read more about Use of Recombinant Parainfluenza Viruses (PIVs) as Vectors To Protect Against Infection and Disease Caused By PIV and Other Human Pathogens Australia20731/01Filed on 2000-12-08
Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination and in Methods of Screeening for Neutralizing Antibodies to Hepatitis E Virus Read more about Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination and in Methods of Screeening for Neutralizing Antibodies to Hepatitis E Virus European Patent00982311.3Filed on 2000-11-30
Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors Read more about Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors European Patent00989184.7Filed on 2000-09-22
Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors Read more about Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors Canada2385122Filed on 2000-09-22
Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloprteinases or Plasminogen Activator Receptors Read more about Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloprteinases or Plasminogen Activator Receptors Australia25725/01Filed on 2000-09-22
Identification of the Domain of Plasmodium Falciparum Erythrocyte Membrane Protein 1(PFEMP1) that Mediates Adhesion to Chondroitin Sulfate A Read more about Identification of the Domain of Plasmodium Falciparum Erythrocyte Membrane Protein 1(PFEMP1) that Mediates Adhesion to Chondroitin Sulfate A European Patent00961513.9Filed on 2000-09-01
Production Of Recombinant Respiratory Syncytial Viruses Expressing Immune Modulatory Molecules Read more about Production Of Recombinant Respiratory Syncytial Viruses Expressing Immune Modulatory Molecules Mexico2002-000490Filed on 2000-07-12